Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

Clinical Infectious Diseases

Volumn 65, Issue 1, 2017, Pages 158-161

  Munita, Jose M ^a,b,c,d   Aitken, Samuel L ^a,e   Miller, William R ^a,b   Perez, Federico ^g   Rosa, Rossana ^h,i   Shimose, Luis A ^h,i   Lichtenberger, Paola N ⁱ   Abbo, Lilian M ^h,i   Jain, Rupali ^j   Nigo, Masayuki ^b   Wanger, Audrey ^c   Araos, Rafael ^d   Tran, Truc T ^a,b   Adachi, Javier ^f   Rakita, Robert ^k   Shelburne, Samuel ^f   Bonomo, Robert A ^g   Arias, Cesar A ^a,b,l  

^a Center for Antimicrobial Resistance and Microbial Genomics   (United States)

^b Division of Infectious Diseases   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSIDAD DEL DESARROLLO   (Chile)

^e Division of Pharmacy   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h JACKSON MEMORIAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j Department of Pharmacy ^*  (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

^l UNIVERSIDAD EL BOSQUE   (Colombia)

more..

Author keywords

carbapenem resistant; Ceftolozane; multidrug resistant; P. aeruginosa

Indexed keywords

CARBAPENEM; CEFTOLOZANE PLUS TAZOBACTAM; CIPROFLOXACIN; COLISTIN; TOBRAMYCIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; TAZOBACTAM;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECT; MICROBIOLOGY; MULTICENTER STUDY;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CEPHALOSPORINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 85021792400     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix014     Document Type: Article

References (16)

1. Van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: Second-generation-lactam/-lactamase inhibitor combinations. Clin Infect Dis 2016; 63:234-41.
2. ZERBAXA (ceftolozane/tazobactam) product package insert. Whitehouse Station, NJ: Merck, 2014.
3. Sutherland CA, Nicolau DP. Susceptibility profile of ceftolozane/tazobactam and other parenteral antimicrobials against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa from US hospitals. Clin Ther 2015; 37:1564-71.
4. Walkty A, Karlowsky JA, Adam H, et al. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrob Agents Chemother 2013; 57:5707-9.
5. Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U. S. hospitals (2011-2012). Antimicrob Agents Chemother 2013; 57:6305-10.
6. Centers for Disease Control and Prevention. National Healthcare Safety Network surveillance definitions for specific types of infections (January 2016). Available at: Http://www. cdc. gov/nhsn/PDFs/pscManual/17pscNosInfDef-current. pdf. Accessed 15 November 2016.
7. US Food and Drug Administration. FDA Approval Label for Zerbaxa. Available at: Http://www. accessdata. fda. gov/drugsatfda-docs/label/2014/206829lbl. pdf. Accessed 15 November 2016.
8. Gelfand MS, Cleveland KO. Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin Infect Dis 2015; 61:853-5.
9. Buehrle DJ, Shields RK, Chen L, et al. Evaluation of the in vitro activity of ceftazidime-A vibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother 2016; 60:3227-31.
10. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43(suppl 2):S49-56.
11. Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis 2013; 56:398-404.
12. Gibson GA, Bauer SR, Neuner EA, Bass SN, Lam SW. Influence of colistin dose on global cure in patients with bacteremia due to carbapenem-resistant gram-negative bacilli. Antimicrob Agents Chemother 2015; 60:431-6.
13. Hachem RY, Chemaly RF, Ahmar CA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 2007; 51:1905-11.
14. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37:e154-60.
15. Levin AS, Barone AA, Pen J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008-11.
16. Benattar YD, Omar M, Zusman O, et al. The effectiveness and safety of high-dose colistin: Prospective cohort study. Clin Infect Dis 2016; 63:1605-12.